Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients

• Published in: Clinical endocrinology (Oxford) Vol. 75; no. 5; pp. 650 - 655
• Main Authors: Hensen, E. F., Siemers, M. D., Jansen, J. C., Corssmit, E. P. M., Romijn, J. A., Tops, C. M. J., van der Mey, A. G. L., Devilee, P., Cornelisse, C. J., Bayley, J. P., Vriends, A. H. J. T.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-11-2011; Blackwell; Wiley Subscription Services, Inc
• Subjects: Adult; Biological and medical sciences; Endocrinopathies; Female; Fundamental and applied biological sciences. Psychology; Head and Neck Neoplasms - genetics; Head and Neck Neoplasms - pathology; Humans; Male; Medical sciences; Membrane Proteins - genetics; Middle Aged; Mutation; Netherlands; Neurology; Paraganglioma - genetics; Paraganglioma - pathology; Succinate Dehydrogenase - genetics; Tumors of the nervous system. Phacomatoses; Vertebrates: endocrinology; Netherlands; Europe; Human; Symptomatology; Nervous system diseases; Determinant; Diseases of the autonomic nervous system; Paraganglioma; Head and neck; Tumor; Patient; Mutation; Dutch; Endocrinology
• ISSN: 0300-0664; 1365-2265
• DOI: 10.1111/j.1365-2265.2011.04097.x

Summary
Objective  Head and neck paragangliomas (HNPGL) are associated with mutations in genes encoding subunits of succinate dehydrogenase (SDH). The aim of this study was to evaluate SDH mutations, family history and phenotypes of patients with HNPGL in the Netherlands.
Design  We evaluated the clinical data and the mutation status of 236 patients referred between 1950 and 2009 to Leiden University Medical Center.
Results  The large majority of the patients carried mutations in SDHD (83%), and the p.Asp92Tyr Dutch founder mutation in SDHD alone accounted for 72% of all patients with HNPGL. A mutation in SDHAF2 was found in 4%, mutations in SDHB in 3% and a mutation in SDHC was identified in a single patient (0·4%). Over 80% of patients presented with positive family history, of whom 99·5% carried a mutation in an SDH gene. SDH mutations were also found in 56% of isolated patients, chiefly in SDHD (46%), but also in SDHB (8%) and SDHC (2%). The clinical parameters of these different subgroups are discussed: including the age at diagnosis, associated pheochromocytomas, tumour multifocality and malignancy rate.
Conclusion  The majority of Dutch patients with HNPGL present with a positive family history, in contrast to other European countries. The clinical characteristics of patients with HNPGL are chiefly determined by founder mutations in SDHD, the major causative gene in both familial and isolated patients with HNPGL. The high frequency of founder mutations in SDHD suggests a higher absolute prevalence of paraganglioma syndrome in the Netherlands.